Pembrolizumab for Breast Cancer

"Pembrolizumab is a viable therapeutic option for those with malignant melanoma of the skin, recurrent cervical cancer and leukemia."

"This clinical trial is not currently open for enrollment. It was initially published on October 18th 2016 and has since been updated November 8th 2022. For those seeking other similar studies, there are 2351 trials actively recruiting patients with breast cancer, as well as 1746 medical studies involving Pembrolizumab that are presently looking to enroll participants."

"Pembrolizumab's safety is rated 2, as the drug has already been tested and some evidence of its security exists. However, no studies have demonstrated it to be effective yet."

"The clinical trial for which you are searching is no longer recruiting participants. It was initially posted on October 18th 2016, and the last update occurred November 8th 2022. If seeking other trials, there are over 4000 studies actively looking for patients with breast cancer or Pembrolizumab related illnesses."

"Since 1997, Pembrolizumab has undergone 1329 clinical trials with City of Hope Comprehensive Cancer Center. At this current moment in time, the drug is being tried and tested on 1746 participants from various locations including Pittsburgh, Pennsylvania."

"The investigation is presently running in 5 diverse areas, including Pittsburgh, Raleigh and Greensboro. It is recommended to select the closest clinic if you are considering taking part so as to reduce transportation requirements."

"This clinical trial, with a duration of up to two years, aims to quantify the decrease in regulatory T cells (Tregs). Secondary objectives include measuring the duration of response, assessing any treatment-associated toxicity and computing the disease control rate. The best responses for each patient will be measured by RECIST v1.1 criteria which includes complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)."